LIVE WEB BROADCAST EVENT REGISTRATION PAGE

Quzyttir: Learn More About the First and Only 2nd Generation IV Antihistamine


 

You are invited to participate in a Live Interactive Web Broadcast Event! To participate, please complete the information below and click "Submit". You will receive a registration confirmation email with the program login information.

This registration site is funded and developed by TerSera and is intended for healthcare professionals only.

UPCOMING EVENTS

Choose a program from the list below to attend

PROGRAM FOCUS:
Hospitals: Clinical Overview and Use of Quzyttir


PROGRAM FOCUS:
Infusion Centers: Clinical Overview and Use of Quzyttir


* All fields marked with an asterisk are required

If you wish to receive a text reminder, please provide your cell phone number above
(enter your 10-digit phone number with no other characters, e.g., 5551234567).


By submitting this form, I verify that I am a healthcare professional and agree to the privacy policy below.

We respect your privacy. By submitting this form, I understand that the information I have provided will be used by TerSera and its contracted third parties to contact me by mail, email, and/or phone with helpful information on TerSera treatments and indicated conditions. TerSera will not sell or transfer my name or contact information to any third party for their marketing use.

I understand that I may revoke this Authorization at any time by sending written notice of revocation to TerSera Therapeutics at 520 Lake Cook Rd, Suite 500, Deerfield, IL, 60015, except to the extent that action already has been taken in reliance on this Authorization.



PRESENTED BY:

Joseph Moellman, MD
Professor of Emergency Medicine,
University of Cincinnati College of Medicine
Cincinnati, Ohio






Dr. Joseph Moellman currently serves as Professor of Emergency Medicine at the University of Cincinnati College of Medicine. He attended the University of Cincinnati College of Medicine (1988-1992) and subsequently completed a 4-year Emergency Medicine residency at the University of Cincinnati, the very first emergency residency in the country. Since 1996, Dr. Moellman has been on faculty at the University of Cincinnati College of Medicine in which he serves several roles, including the clinical practice of emergency medicine, mentoring and teaching emergency medicine residents and participating in clinical research.

READ MORE +

Dr. Moellman’s major focus of study is in the field of allergy and immunology as it pertains to emergency medicine. More specifically, the topic of general angioedema and angiotensin converting enzyme inhibitor associated angioedema is his major focus. He collaborates with Dr. Jonathan Bernstein (Director of Allergy and Immunology at the University of Cincinnati) who is an international expert on angioedema. Over the past several years, Dr. Moellman has been co-principal investigator in several trials looking at novel agents for the treatment of ACE inh angioedema including Ecallantide and Icatibant. He likewise has written extensively on the subject for various journals and textbook chapters on angioedema as well as anaphylaxis. One of his greatest accomplishment was forming a working group of emergency physicians and leading allergist to craft a "Consensus Parameter for the Emergency Evaluation and Treatment of Angioedema" which is frequently referenced in the emergency medicine literature. Dr. Moellman’s work exploring novel treatments and evaluation of such patients continues today.

Dr. Moellman is currently an editorial board member for the Journal of Asthma as well as serves as a reviewer for the Canadian Journal of Emergency Medicine and the Journal of Emergency Medicine.

Besides his major focus of allergy and immunology, Dr. Moellman participates and is a member of the Emergency Medicine Clinical Trials Center at the University of Cincinnati having served as a sub investigator in the Mercury trial for Pulmonary Embolism as well as various other trials.

Dr. Moellman has served as consultant to CSL Berhing, Shire, JDP Therapeutics and most recently TerSera Therapeutics.




  
  
  

Timothy Tyler, PharmD, FCSHP, FHOPA
Director of Pharmacy, Lab & Oncology Supportive Care Services,
Desert Regional Medical Center - Comprehensive Care Center
Palm Springs, California







Dr. Timothy Tyler is the Director of Pharmacy, Lab and Oncology Supportive Care Services at the Comprehensive Cancer Center at Desert Regional Medical Center in Palm Springs, California. He is responsible for ambulatory oncology care in the main center as well as a satellite on the other end of the Coachella Valley and includes pain management and medication use in all clinics and has held this position since 1994. Dr. Tyler is also co-chair of the Complementary Medicine Program and leader of the pain service. He has served as adjunct clinical faculty at the University of Southern California for the past 25 years.

READ MORE +

In 2001, during the shift in outpatient reimbursement landscape, Dr. Tyler was appointed to the OPPS Medicare Advisory Panel where he served for 4.5 years, the last two as the chair of the data subcommittee. He has been an advisor to the pharmaceutical industry and also a much sought after speaker on numerous speakers bureaus. He was involved in the creation of HOPA, the Hematology Oncology Pharmacy Association and recently completed his second tour of duty as the national health policy chairman for the 15-year-old organization.

Dr. Tyler possesses an undergraduate degree in Business Administration from the California State University, San Bernardino and he received his Doctor of Pharmacy degree from the University of Southern California in Los Angeles. He was instrumental in the creation of the pharmacy residency program at Desert Hospital (now Desert Regional Medical Center) in Palm Springs as its first resident in 1993. Dr. Tyler was made a Fellow in the California Society of Health System Pharmacists in 2002 and in 2017 was made a Fellow in the Hematology Oncology Pharmacy Association. His oncology-based lectures are wide ranging and contain his signature wit and humor, giving approximately 30-40 of them yearly. He has been invited to keynote several healthcare meetings in the past in the US and abroad and continues to be an invited lecturer at meetings for physicians, pharmacists, and nurses around the country and the globe.




  
  
  

For assistance, please contact us at nlauffenberger@vision2voice.com. Hours of operation are Monday-Friday, 8:30 AM - 5:00 PM Central Time.

 

Important Safety Information and Indication

Click to Open

IMPORTANT SAFETY INFORMATION

Contraindications: Known hypersensitivity to QUZYTTIR or any of its ingredients, to levocetirizine, or hydroxyzine.

Additional Warnings and Precautions: The occurrence of somnolence/sedation has been reported in some patients. Advise patients to exercise due caution when driving or operating potentially dangerous machinery. Avoid concurrent use of QUZYTTIR with alcohol or other CNS depressants because additional reduction in alertness and additional impairment of CNS performance may occur.

 
 

Adverse Reactions: The most common adverse reactions (incidence <1%) with QUZYTTIR are dysgeusia, headache, paresthesia, presyncope, dyspepsia, feeling hot, and hyperhidrosis.

The most common adverse reactions (incidence ≥2%) with chronic dosing of oral cetirizine hydrochloride in adults are somnolence, fatigue, dry mouth, pharyngitis and dizziness. Adverse reactions observed in pediatric patients with chronic use of oral cetirizine hydrochloride are headache, pharyngitis, abdominal pain, coughing, somnolence, diarrhea, epistaxis, bronchospasm, nausea, and vomiting.

For more information, please see the full Prescribing Information for QUZYTTIR.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088. You can also contact TerSera Therapeutics at 1-844-334-4035 or medicalinformation@tersera.com.

INDICATIONS AND USAGE

QUZYTTIR is indicated for the treatment of acute urticaria in adults and children 6 months of age and older.
Limitations of Use: QUZYTTIR is not recommended in pediatric patients <6 years of age with impaired renal or hepatic function.